| 2026-08-11 | Press release | SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-08-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-27 | 8-K | Form 8-K, Item 2.02 results |
| 2026-06-25 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-18 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-02 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-14 | Press release | SELLAS Life Sciences to Participate in Upcoming Investor Conferences |
| 2026-05-12 | Press release | SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-12 | Press release | SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-12 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-23 | Proxy | Definitive proxy statement |
| 2026-03-19 | Press release | SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update |
| 2026-03-19 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-19 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-17 | Press release | SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference |
| 2026-03-17 | Press release | SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conferen |
| 2026-03-12 | Press release | Download PDF, SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS0 |
| 2026-03-12 | Press release | SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 |
| 2026-03-11 | 8-K | Form 8-K, Item 8.01 |
| 2026-01-14 | Press release | Download PDF, SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe, Janua |
| 2026-01-14 | Press release | SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe |
| 2026-01-08 | 8-K | Form 8-K, Item 2.02 results |
| 2025-12-29 | Press release | SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (A |
| 2025-12-29 | Press release | SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (A |
| 2025-12-07 | Press release | SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR |
| 2025-12-07 | Press release | SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR |
| 2025-11-12 | Press release | SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update – Hosted Virtual R&D Day Highlighting GPS and SLS009 Programs in AML |
| 2025-11-12 | Press release | SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-11-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-12 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-11-03 | Press release | SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in |
| 2025-11-03 | Press release | SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in |
| 2025-10-27 | Press release | SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Mill |
| 2025-10-27 | 8-K | Form 8-K, Item 1.01 |
| 2025-10-22 | Press release | SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum |
| 2025-10-13 | Press release | SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS |
| 2025-10-03 | 8-K | Form 8-K, Item 1.01 |
| 2025-09-30 | Press release | SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leuke |